Jennifer L. Good - 20 May 2024 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role: President & CEO, Director
Signature: /s/ Christopher Galletta, attorney-in-fact
Issuer symbol: TRVI
Transactions as of: 20 May 2024
Net transactions value: -$16,745
Form type: 4
Filing time: 22 May 2024, 16:30:37 UTC
Previous filing: 14 May 2024
Next filing: 20 Jun 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TRVI	Common Stock	Options Exercise	$54,831	+25,037	+12%	$2.19	238,350	20 May 2024	Direct
transaction	TRVI	Common Stock	Sale	$71,576	-25,037	-11%	$2.86	213,313	20 May 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TRVI	Stock Option (right to buy)	Options Exercise	$0	-25,037	-43%	$0.000000	33,189	20 May 2024	Common Stock	25,037	$2.19	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.82 to $2.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F2	This option was granted on July 2, 2014. The 62,804 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.82 to $2.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

This option was granted on July 2, 2014. The 62,804 shares of common stock underlying the option vested as to 25% of the shares on June 11, 2015 and vested as to the remaining 75% of the shares in equal monthly installments thereafter through June 11, 2018.